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Background: Systematic review (SR) of randomized controlled trials (RCT) is the gold standard for informing treatment
choice. Decision analyses (DA) also play an important role in informing health care decisions. It is unknown how often
the results of DA and matching SR of RCTs are in concordance. We assessed whether the results of DA are in
concordance with SR of RCTs matched on patient population, intervention, control, and outcomes.
Methods: We searched PubMed up to 2008 for DAs comparing at least two interventions followed by matching SRs of
RCTs. Data were extracted on patient population, intervention, control, and outcomes from DAs and matching SRs of
RCTs. Data extraction from DAs was done by one reviewer and from SR of RCTs by two independent reviewers.
Results: We identified 28 DAs representing 37 comparisons for which we found matching SR of RCTs. Results of the
DAs and SRs of RCTs were in concordance in 73% (27/37) of cases. The sensitivity analyses conducted in either DA or
SR of RCTs did not impact the concordance. Use of single (4/37) versus multiple data source (33/37) in design of DA
model was statistically significantly associated with concordance between DA and SR of RCTs.
Conclusions: Our findings illustrate the high concordance of current DA models compared with SR of RCTs. It is
shown previously that there is 50% concordance between DA and matching single RCT. Our study showing the
concordance of 73% between DA and matching SR of RCTs underlines the importance of totality of evidence
(i.e. SR of RCTs) in the design of DA models and in general medical decision-making.Background
Medical decision-making requires a comprehensive analysis
of benefits and harms associated with available treatment
options. Randomized controlled trials (RCTs), and in turn
systematic reviews (SRs) of RCTs, are considered the refer-
ence standard in resolving treatment uncertainties [1,2].
However, in many instances RCTs and in turn SR of RCTs
lack the power and long duration of follow up needed to
assess the long-term outcome estimates [3]. Decision ana-
lysis (DA) can be used to provide the required estimates to
inform medical decision-making [4].
Decision analysis models have been used in medical-
decision making since 1972 [5-7]. For a DA model to be* Correspondence: hwao1@health.usf.edu
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reproduction in any medium, provided the oruseful and applicable it should reflect real problems of
patients and data on clinical outcome probabilities
should be generated using a systematic approach. While
DAs can allow users to make informed decisions when
confronted with difficult clinical scenarios, their over-
simplification of real world scenarios can be problematic
[8]. DA models are often based on data derived from
empirical studies with short-term follow up and the
biases from these studies influence modeled outcomes
[3]. Although there are guidelines for assessing the use-
fulness of DA and their role in medical decision-making
[9,10] very few studies have assessed the soundness of
DAs. That is, how often DA results agree with findings
of matching RCTs or SR of RCTs (published after the DA)
has not been comprehensively investigated. We are aware
of two studies that have assessed the soundness of DA
using subsequent clinical study results [11,12]. The studyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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determined that findings of DAs were in concordance with
findings of clinical studies (including RCTs and observa-
tional studies) in 75% of the cases assessed [11]. We have
previously shown that findings of DAs and matching RCTs
are in concordance only 50% of the time [12]. However, it
is not known how often findings of DAs correspond with
matching SRs of RCTs. Accordingly, the objective of this
study is to assess how often findings of DAs are in concord-
ance with matching SRs of RCTs.
Methods
Eligibility criteria
Decision analyses comparing two or more treatments were
eligible for inclusion in this study. Systematic reviews of
RCTs published after the matching DA models were in-
cluded. That is, SR of RCTs published before the matching
DA was not included in this study. If a matching SR for an
included DA model was not found, the DA was excluded
for the study.
Information sources
We searched PubMed and Cochrane library for identifying
DA and matching SR of RCTs.
Search strategy: decision analysis papers
“Decision Support Techniques” was introduced as medical
subject heading term in year 2000. Hence, we searched
PubMed (Medline) for DAs from 01/2000 to 12/2008 for
DAs using the following search strategy: (“Decision Support
Techniques”[Mesh] OR (“Decision Making”[Mesh])
OR (“Decision Analysis”) AND (“Therapeutics”[Mesh]
OR “therapy ”[Subheading] OR “Treatment Outcome”
[Mesh] OR “Therapies, Investigational”[Mesh])).
Search strategy: systematic reviews of RCTs
We searched PubMed and Cochrane library for systematic
reviews (SRs) of RCTs that matched the identified DAs
based on patient population (P), intervention (I), control (C)
and outcome (O) (PICO) criteria. Clinical Queries search
strategies in Pubmed which have been updated based on
the filter developed by Haynes et al. were also utilized to
search for SRs of RCTs matching the DAs [13]. Systematic
reviews of RCTs published after the matching DA models
were included. Keywords from DA intervention and control
arms were used and, if necessary, search returns were nar-
rowed by using keywords from the DA patient population.
Study selection
Abstracts of all the identified studies were reviewed by
one reviewer (RM) for inclusion according to the pre-
determined criteria. In addition, 2 reviewers (BD and AK)
randomly selected and reviewed 15% of the citations for
inclusion to assess for accuracy. Another set of reviewers(HG and HW) reviewed list of all citations to identify
matching SRs of RCTs for the included DAs. The list of
matched SR of RCTs and DA were further confirmed in-
dependently by 2 reviewers (RM and AK). Any disagree-
ments in the selection process of DA and matching SR
of RCTs were resolved by consensus.
Data extraction
Data were extracted from each included DA and SR of
RCTs using a standardized data extraction form. Data
were extracted on PICO elements from all DAs and
matching SRs of RCTs. From each DA we also extracted
data on whether single versus multiple data sources were
used the design of DA model. From each included SR of
RCTs data were also extracted on the number of RCTs
included, sample size and year of publication. Data abstrac-
tion from included DAs was done by one reviewer (RM)
and from SR of RCTs by two reviewers (HG and HW).
Senior reviewers (BD and AK) randomly selected and
reviewed 15% of the extracted data from included stud-
ies to assess for accuracy.
Outcomes
Matching of DA and SR of RCTs
Abstracts of identified SRs of RCTs were reviewed by
two reviewers (HW and HG) independently to deter-
mine the degree of matching based on PICO elements
as follows: Overall the matching of DA and SR was done
for all individual PICO elements at 3 levels classified either
as optimum, broad or broadest match. First the match was
done at participant/patient population level followed by
intervention(s), control and outcome(s). If the initial match
at participant/disease level was not achieved, the DA was
excluded from the review. PICO elements of SR of RCTs
were considered an optimum match to a DA if it involved
same PICO elements. The PICO elements of SR of RCTs
were considered a broad match to a DA if it involved simi-
lar PICO elements. The PICO elements of SR of RCTs were
considered a broadest match to a DA if it involved only
slightly similar PICO elements.
Examples of optimum, broad and broadest match are
shown in Table 1. In situations where multiple matches
were found, the most recently published SR of RCTs
was chosen.
Concordance and impact of sensitivity analysis
It is well established that majority of the DAs conduct
and report sensitivity analyses and the final outcomes of
the DA model may be influenced by these sensitivity
analyses. Hence, to assess the impact of the DA outcomes
after these sensitivity analyses on the concordance or dis-
cordance with the findings of matching SR of RCTs we ex-
tracted data on the sensitivity analyses. Specifically, for
each included DA and SR of RCTs, two review authors
Table 1 Examples of matching based on PICO elements
PICO element Decision analysis Systematic review of RCTs Matching category
Participant (P) “premenopausal women with newly diagnosed
hormone responsive breast cancer” [14]
“premenopausal women with early breast cancer
which was responsive for estrogen receptor” [15]
Optimum
“women with breast cancer” [16] “women with early stage breast cancer” [17] Broad
“ high risk women seeking prophylactic
mastectomy” [18]
“women with invasive breast cancer” [19] Broadest
Intervention (I)/Control (C) “breast conserving surgery” (intervention) and
“mastectomy” (control) [16]
“breast conserving surgery” (intervention) and
“mastectomy” (control) [20]
Optimum
“medical ovarian suppression or surgical
ovarian suppression” (intervention). [14]
“medical ovarian suppression” (intervention) [15] Broad
“conservation therapy (medical and other methods)”
(control) [21]
“medical therapy” for patients with non-acute
coronary artery disease (control) [22]
Broad
“surgery” (intervention) [23] “laser excision” in patients with glottic cancer
(intervention) [20]
Broadest
Outcome (O) “overall survival” [14] “overall survival” [15] Optimum
“complications” [18] “morbidity” [19] Broad
“breast cancer mortality” [24] “all-cause mortality” [25] Broadest
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overall conclusion (indicating which treatment was better);
whether author’s conclusion changed after sensitivity
analysis and whether the conclusion(s) of DA and SR of
RCTs agreed or disagreed. Discrepancies between the
two reviewers’ judgments were resolved by discussion
and mutual consensus with other reviewer (RM).
Statistical analysis
We used descriptive statistics to report concordance or
discordance between results of DA and SR of RCTs. Impact
of variables that are used in the construction of DA model
on concordance between DA and matching SR of RCTs
was assessed by Fishers’ exact test. The impact of sample
size of SR of RCTs on concordance of findings between DA
and SR of RCTs was tested using Kruskal–Wallis one-way
analysis of variance test [26].
Results
Study selection
The PubMed search for DAs yielded 42,704 citations
(Figure 1). We excluded 42,617 studies after reviewing
abstracts and found 87 studies that used DA modeling
to compare two or more interventions. We found
matching SR of RCTs for 32% (28/87) of DAs. These 28
DAs included 37 comparisons for which we found a
matching SR of RCTs.
Characteristics of included DAs and SRs
Infection (11/37) and cancer (10/37) were the most fre-
quently studied diseases using DA modeling. The included
DAs investigated effects of medications in 56% (21/37) of
cases compared with surgical interventions in 38% (14/37)
of cases (Table 2). Ninety five percent (35/37) of DAs didnot collect any primary data and used data published in the
literature in designing DA model. Only 5% (2/37) of DA
models used a systematic approach (e.g. meta–analysis)
to data collection. Similarly, 5% (2/37) of DA models used
expert opinion in designing the DA model. Ninety seven
percent (36/37) of DAs conducted sensitivity analysis
while 51% (19/37) of included SRs of RCTs conducted
sensitivity or sub-group analysis. The median sample size
of included SR of RCTs was 2610 (range: 42 to 32523).
Matching between DA and SR of RCTs
As summarized in Table 3 the match between DA par-
ticipant characteristics with SR of RCTs was considered
optimum in 57% (21/37), broad in 21% (8/37) and broadest
in 18% (8/37) of cases, respectively. The match for inter-
ventions studied in DAs with interventions in the SR of
RCTs was optimum in 95% (35/37) and broad and broadest
in 1/37 cases each. Similarly, the matching of controls in
DA with the controls used in the SR of RCTs was optimum
in 92% (34/37), broad in 5% (2/37) and broadest in 3%
(1/37) of cases (Table 3).
Concordance between findings of DA and SR of RCTs
Overall, the findings of the DAs and the SRs of RCTs were
in concordance in 73% (27/37) of cases. Twenty-seven per-
cent (10/37) of the SR of RCTs findings were discordant
with the findings of the DA (Figure 2).
Out of the 21 pairs of DA and SR with the optimum
match of the patient characteristics 66% (14/21) of the
DA findings were in concordance with the findings of
the matching SR of RCTs. Out of the 8 pairs of DA and
SR with the broad match of the patient characteristics
87% (7/8) of the DA findings were in concordance with
the findings of the matching SR of RCTs. Out of the 8
Figure 1 Flow diagram depicting study selection process.
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tient characteristics 75% (6/8) of the DA findings were
in concordance with the findings of the matching SR of
RCTs. There was no association between degree of match-
ing based on patient characteristics and concordance of
findings of DAs and SR of RCTs (p = 0.52). Similarly, there
was no association between degree of matching based on
intervention characteristics (p = 0.21) and control charac-
teristics (p = 0.17) and concordance of findings of DAs and
SR of RCTs.
The majority of the sensitivity analyses conducted in DA
(33/37) did not impact the concordance between findings
of DA and matching SR of RCTs. In three cases, the find-
ings of DA and matching SR of RCTs were similar after the
sensitivity analysis [14,16,27].
Impact of decision analysis design attributes on concordance
The findings of DAs using multiple data sources were
more likely to be concordant with matching SRs of
RCTs than DAs using single data source and this associ-
ation reached statistical significance (p = 0.05) (Table 4).Incorporation of data from meta-analysis (p = 1.00), use of
expert opinion (p = 0.06) and primary versus secondary
data collection (p = 0.47) in the design of DA model did
not have any impact on concordance between findings of
DA and SR of RCTs (Table 4). It is important to note that,
the meta analysis used to inform the design of the DAs
were obviously published before the DA model and were
not used for matching the results of DAs and SRs. The
distribution of sample size of SR of RCTs was similar
across the SRs which were in concordance with the find-
ings of their matched DAs compared with SRs with the
findings discordant with their matched DAs (p = 0.78).
Discussion
Summary of evidence
To our knowledge, this is the first SR to date comparing
the results of DAs with matching SRs of RCTs. The find-
ings show that there is high level of concordance between
findings of DA and matching SRs of RCTs and use of mul-
tiple sources of data in decision analyses appears to increase
the predictive value of DA.
Table 3 Degree of matching between DA and SR of RCTs
Category N (%)
Patient
Matching with optimum criteria 21 (56.8)
Matching with broad criteria 8 (21.6)
Matching with broadest criteria 8 (21.6)
Intervention
Matching with optimum criteria 35 (94.6)
Matching with broad criteria 1 (2.7)
Matching with broadest criteria 1 (2.7)
Control
Matching with optimum criteria 34 (91.9)
Matching with broad criteria 2 (5.4)
Matching with broadest criteria 1 (2.7)
Table 2 Characteristics of decision analysis and
systematic review of RCTs
Characteristic N (%)
DA Disease category
Infectious diseases 11 (29.7)
Cancer 10 (27)
Cardiovascular disease 5 (13.5)
Venous ailments 3 (8.1)
OB/GYN 2 (5.4)
Other 6 (16.2)
Pressure ulcers 2 (2)
Crohns disease 1 (1)
Obesity 1 (1)
Achilles Tendon Rupture 1 (1)




Abstaining from breast feeding 1 (3)





Breast feeding 2 (5.4)
Radiation 1 (2.7)
Placebo 1 (2.7)
SR of RCTs characteristic
Median sample size (range) 2610 (42–32523)
Figure 2 Concordance between findings of decision analysis
(DAs) and systematic review of RCTs.
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popularity and employs assessment of multiple interven-
tions by comparing their long-term outcomes. However,
in many instances the RCTs and other studies that are
used in CER lack the power and long duration of follow
up needed to assess the long-term outcome estimates
[3]. Over past 39 years, DA has been applied to a variety
of clinical problems to provide these much desired esti-
mates to improve clinical decision making. However, the
concordance between findings of empirical efficacy studies
that are used for decision making (i.e. RCTs) and DA find-
ings is not known. This largest SR to date shows concord-
ant findings of DAs and matching SRs of RCTs in 73% of
cases. The findings from our study also emphasizes on the
importance of SR as we have previously shown that results
of DAs and matching single RCT disagree about only 50%
of the time [12].Table 4 Impact of DA design attributes on concordance







Single data source 1(25) 3(75) 0.05
Multiple data source 26(79) 7(21)
Data from
meta-analysis used
Yes 2(100) 0(0) 1.0
No 25(71) 10(29)
Expert opinion used




Yes 1(50) 1(50) 0.47
No 26(74) 9(26)
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study on the topic. The study by Bress et al. focused on
infectious diseases and assessed the concordance of DA
findings compared with subsequent clinical study results
[11]. The study by Bress et al. determined that findings
of DAs were in concordance with findings of clinical
studies in 75% of the cases assessed [11]. However, the
study by Bress et al. was limited to the field of infectious
diseases and compared findings of DAs with either RCTs
or observational studies [11]. Moreover, this study by
Bress et al. did not comprehensively report the impact
of DA design attributes and sample size of matching
SRs on concordance between findings of DAs and SRs.
We also explored the reasons for concordance and dis-
cordance between findings of DAs and matching SRs
of RCTs employing multiple analyses. Specifically, we
investigated the impact of DA design factors and sam-
ple size of matching SR of RCTs on concordance and
discordance between findings of DA and SR of RCTs.
Our results indicate that none of the attributes except
use of single versus multiple data source in the design
of DA models is significantly associated with concordance
of findings between DA and matching SR of RCTs. Sample
size of matching SR of RCTs did not have any impact on
concordance and discordance between findings of DAs
and SR of RCTs either. Another factor that may impact
concordance between findings of DA and SR is the degree
of matching between DA and SR PICO attributes which
was performed in our study. In our study, the intervention
and controls studied in DAs closely matched with SRs in
majority of the cases. However, patient population en-
rolled in DAs closely matched with SR in 57% of cases.
Nonetheless, the degree of patient population matching
did not have any impact on concordance between findings
of DA and SR of RCTs.
Limitations
Our study has some limitations. There were a relatively
small number of published DAs and an even smaller num-
ber with matching SR of RCTs. However, since DAs are
mostly conducted when a RCT is not available this was
expected. Nonetheless, our findings are based on small
sample size (n = 37) and hence should be interpreted with
caution. We did not search for unpublished DAs or SR of
RCTs. As noted by Bress et al., our literature search also
could not distinguish DA from other study designs. If
“decision analysis” were a MeSH term, such searches
would be more efficient and reproducible [11]. As a result,
we reviewed large volume of citations (n = 42,704) and
hence our search is not updated since 2008.
Conclusions
Our results show the high concordance of findings of
current DA models compared with findings of SR ofRCTs. Moreover, our results outline the importance of SR
of RCTs compared with a single RCT in medical decision
making. That is, the concordance between DA findings
and matching single RCT findings was only 50% [12] but
the concordance between findings of DA and matching
totality of evidence (i.e. SR of RCTs) was 73%. This under-
scores the importance of use of research synthesis in med-
ical decision making.
Our study findings are important and informative to the
design of DA models. It is known that, unless all clinically
important factors have been included, the DA lacks suffi-
cient representativeness to be clinically useful [7,28-30].
Moreover, DA designs need to follow a consistent set
of best practices for selecting (estimates from SR/MA
rather than individual studies), adjusting for bias and
incorporating empirical evidence [3,31-33]. Our findings
further highlight the need of further investigation of
the impact of DA design attributes such as use of
meta-analysis data and data from multiple sources on
clinical rationality of DA models. Investigation of influence
of DA design attributes on usefulness of DA model in deci-
sion making will further improve use of DAs in healthcare
decision making and policy development.
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